Viridian Therapeutics (VRDN) received a Buy rating and a $40.00 price target from Ladenburg Thalmann & Co. analyst Michael Higgins today. The company’s shares closed last Friday at $21.78.
According to TipRanks.com, Higgins is a 4-star analyst with an average return of 17.4% and a 38.3% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Rhythm Pharmaceuticals.
Currently, the analyst consensus on Viridian Therapeutics is a Strong Buy with an average price target of $33.00, a 64.3% upside from current levels. In a report issued on January 20, Jefferies also maintained a Buy rating on the stock with a $28.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $34.05 and a one-year low of $4.67. Currently, Viridian Therapeutics has an average volume of 480.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.